Pancreatic amylase, blood

Alphabetical Test listing

Pancreatic amylase, blood-13381

Pancreatic amylase, blood
Amylase fractionation
Pancreatic amylase

Evaluate pancreatic disease.

Amylase is primarily produced in the pancreas and salivary glands. Isoenzymes may be used to determine the source of an elevated amylase concentration. Measurement of pancreatic amylase activity is of value in diagnosing pancreatitis and other pancreatic disorders which result in elevation of serum and urine amylase.

2.0 mL
1.0 mL

Spin within 30 minutes of sample collection


Gold serum separator (SST) tube

Lithium heparin (Li hep) plasma

Spin and separate


Ambient (preferred ) - 7 days

Refrigerated - 30 days

  • Hemolysis
  • Use of anticoagulants other than lithium heparin (citrate and fluoride inhibit the assay reaction)
LabCorp Burlington (123111): R-LC
Mo - Fr
2 - 3 days

Salivary amylase is inhibited by specific antibodies and the remaining pancreatic amylase is determined by an enzymatic, colorimetric method.


0 - 1 years:     Not established
2 - 17 years:   12 – 40
18 - 60 years: 14 – 55
>60 years:      13 - 72


Macroamylases are sometimes present in sera. These rare forms are probably complexes between ordinary amylase (usually S-type) and IgA, IgG, or other high molecular weight plasma proteins. These macroamylases cannot be filtered through the glomeruli of the kidney because of their large size (MW >200,000) and are thus retained in the plasma where their presence may increase amylase activity to some six- to eightfold over that observed in health. In macroamylasemia, amylase activity in the urine is lower than normal, since less amylase is cleared by the kidneys. No clinical symptoms are associated with this disorder; however, many of these cases have been detected following investigation of abdominal pain.

Result 1805-1